KRAS and cancer: This is clinically relevant in the context of the SIAH1/2 gatekeeper function, as well as being a signaling bottleneck critical for oncogenic K-RAS activation, and a major tumor vulnerability in oncogenic K-RAS-driven human cancer [72,134,135].